
Passion IT Framework
MAPK4 Presents Novel Therapeutic Target for Treatment of Triple-Negative Breast Cancer
- ByPassionIT News --
- 2022-01-14
With new evidence demonstrating the involvement of the MAPK4 enzyme in cancer growth and therapy resistance, researchers believe the enzyme plays an important role in triple-negative breast cancer (TNBC).
Read More at:
Related News
IRDAI proposes allowing insurers to invest in unlisted firms: sources
Thursday, 01 Jan, 1970
IRDAI proposes allowing insurers to invest in unlisted firms: sources
Thursday, 01 Jan, 1970
Tulsa, NWA stakeholders start angel investing program
Thursday, 01 Jan, 1970
Comment